Effector Therapeutics Inc (NASDAQ:EFTR) — Market Cap & Net Worth
Market Cap & Net Worth: Effector Therapeutics Inc (EFTR)
Effector Therapeutics Inc (NASDAQ:EFTR) has a market capitalization of $940.00 ($940.00) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31810 globally and #6296 in its home market, demonstrating a -66.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Effector Therapeutics Inc's stock price $0.00 by its total outstanding shares 4704409 (4.70 Million). See EFTR capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Effector Therapeutics Inc Market Cap History: 2021 to 2026
Effector Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $973.81 Million to $940.88 (-92.51% CAGR).
Effector Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Effector Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.15x
Effector Therapeutics Inc's market cap is 14.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $973.81 Million | $1.43 Million | $15.80 Million | 680.99x | 61.64x |
| 2022 | $50.29 Million | $3.55 Million | -$12.93 Million | 14.15x | N/A |
Competitor Companies of EFTR by Market Capitalization
Companies near Effector Therapeutics Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Effector Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Effector Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Effector Therapeutics Inc's market cap moved from $973.81 Million to $ 940.88, with a yearly change of -92.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $940.88 | 0.00% |
| 2025 | $940.88 | 0.00% |
| 2024 | $940.88 | -100.00% |
| 2023 | $54.97 Million | +9.31% |
| 2022 | $50.29 Million | -94.84% |
| 2021 | $973.81 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Effector Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $940.00 USD |
| MoneyControl | $940.00 USD |
| MarketWatch | $940.00 USD |
| marketcap.company | $940.00 USD |
| Reuters | $940.00 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Effector Therapeutics Inc
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and a… Read more